**GNOM**
Global X Genomics & Biotechnology ETF

**KEY FEATURES**

**High Growth Potential**
GNOM enables investors to access high growth potential through companies that are positioned to benefit from further advances in the field of genomic science.

**Targeted Exposure**
GNOM provides access to emerging areas within the Health Care Sector at the intersection of science and technology.

**ETF Efficiency**
In a single trade, GNOM delivers access to dozens of companies with exposure to the genomics theme.

**FUND DETAILS**

- **Inception Date**: 04/05/2019
- **Underlying Index**: Solactive Genomics Index
- **Number of Holdings**: 40
- **Assets Under Management**: $200.60 mil
- **Total Expense Ratio**: 0.50%
- **Distribution Frequency**: Semi-Annually

**TRADING DETAILS**

- **Ticker**: GNOM
- **CUSIP**: 37954Y434
- **Exchange**: NASDAQ
- **Bloomberg IOPV Ticker**: GNOMIV
- **Index Ticker**: SOLGNOM

**PERFORMANCE (%)**

<table>
<thead>
<tr>
<th></th>
<th>1M</th>
<th>YTD</th>
<th>1Y</th>
<th>Since Inception</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAV</td>
<td>-6.00%</td>
<td>-5.00%</td>
<td>77.53%</td>
<td>21.35%</td>
</tr>
<tr>
<td>Market Price</td>
<td>-5.86%</td>
<td>-4.83%</td>
<td>78.23%</td>
<td>22.68%</td>
</tr>
<tr>
<td>Index</td>
<td>-5.94%</td>
<td>-4.91%</td>
<td>78.46%</td>
<td>21.99%</td>
</tr>
</tbody>
</table>

**TOP 10 HOLDINGS (%)**

<table>
<thead>
<tr>
<th>Holdings</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pacific Biosci</td>
<td>6.04%</td>
</tr>
<tr>
<td>Natera Inc</td>
<td>5.06%</td>
</tr>
<tr>
<td>Intellia Therapeutics Inc</td>
<td>4.41%</td>
</tr>
<tr>
<td>Crispr Therapeutics Ag</td>
<td>4.27%</td>
</tr>
<tr>
<td>Agilent Technologies Inc</td>
<td>4.15%</td>
</tr>
<tr>
<td>Illumina Inc</td>
<td>4.11%</td>
</tr>
<tr>
<td>Ultragenyx Pharm</td>
<td>3.98%</td>
</tr>
<tr>
<td>Alnylam Pharmace</td>
<td>3.75%</td>
</tr>
<tr>
<td>Arrowhead Pharma</td>
<td>3.70%</td>
</tr>
<tr>
<td>Caredx Inc</td>
<td>3.60%</td>
</tr>
</tbody>
</table>

**INDUSTRY BREAKDOWN (%)**

- **Biotechnology**: 81.00%
- **Medical Specialties**: 11.08%
- **Medical/Nursing Services**: 7.92%

**COUNTRY BREAKDOWN (%)**

- **United States**: 86.42%
- **Netherlands**: 4.66%
- **Switzerland**: 4.27%
- **China**: 2.06%
- **Japan**: 1.39%
- **France**: 0.95%
- **Singapore**: 0.25%

**RISK CHARACTERISTICS SINCE ETF INCEPTION**

<table>
<thead>
<tr>
<th></th>
<th>Solactive Genomics Index</th>
<th>MSCI ACWI Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annualized Volatility</td>
<td>36.82%</td>
<td>20.99%</td>
</tr>
<tr>
<td>Beta</td>
<td>1.21</td>
<td>1.00</td>
</tr>
<tr>
<td>Sharpe Ratio</td>
<td>0.63</td>
<td>0.82</td>
</tr>
</tbody>
</table>
DEFINITIONS

Solactive Genomics Index
The Solactive Genomics Index tracks the companies that generate revenues from Genomics related business. Genomics business operations include the following: (i) gene editing, (ii) genomic sequencing, (iii) development and testing of genetic medicine/therapies, (iv) computational genomics and genetic diagnostics, and/or (v) biotechnology.

MSCI ACWI Index
MSCI ACWI Index captures large and mid cap representation across 23 Developed Markets (DM) and 24 Emerging Markets (EM) countries. The index covers approximately 85% of the global investable equity opportunity set. DM countries include: Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Singapore, Spain, Sweden, Switzerland, the UK and the US. EM countries include: Brazil, Chile, China, Colombia, Czech Republic, Egypt, Greece, Hungary, India, Indonesia, Korea, Malaysia, Mexico, Pakistan, Peru, Philippines, Poland, Russia, Qatar, South Africa, Taiwan, Thailand, Turkey and United Arab Emirates.

Annualized Volatility
The annualized standard deviation of the daily returns of the security using the closing levels of the index during the 22 index-day period preceding that day.

Beta
Measures the volatility of the Fund price relative to the volatility in the market index and can also be defined as the percent change in the price of the Fund given a 1% change in the market index. A beta below one suggests that the Fund was less volatile than the market benchmark.

Sharpe Ratio
Measures the return for each unit of risk. The risk free rate is subtracted from the mean return and is divided by the standard deviation of returns.

Investing involves risk, including the possible loss of principal. The investable universe of companies in which GNOM may invest may be limited. The Fund invests in securities of companies engaged in Genomics, Healthcare and Biotechnology sectors. These sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. GNOM is non-diversified. The information provided is not intended for trading purposes, and should not be considered investment advice.

Carefully consider the Fund’s investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in the Fund’s full or summary prospectus, which may be obtained by calling 1.888.493.8631, or by visiting globalxetfs.com. Please read the prospectus carefully before investing.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares typically do not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in shares, the NAV of the Fund is used to calculate market returns.

Global X Management Company LLC serves as an advisor to the Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO, 1 Freedom Valley Drive, Oaks, PA, 19456), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.